Research · Sep 3, 2026
[OPCH] Option Care Health Thesis 2026: Home Infusion Specialty Pharmacy Compounder
Option Care Health Inc. (NASDAQ: OPCH), headquartered in Bannockburn-IL, is a Home-Infusion-and-Specialty-Pharmacy + emerging-multi-cycle-Home-Infusion-Specialty-Pharmacy-Growth-and-Amber-Specialty-Pharmacy-Acquired-2024 leader providing distinctive multi-cycle Home-Infusion-Acute-and-Chronic-and-Rare-and-Complex-Disease + emerging-Amber-Specialty-Pharmacy-Limited-Distribution-Drug-and-Specialty-Pharmacy + emerging-Site-of-Care-Shift-from-Hospital-to-Home-Infusion + emerging-Biologics-Infusion services to substantial multi-cycle Home-Infusion-Patient (Acute-Anti-Infective-Antibiotic-and-TPN-and-Pain-Management + Chronic-Inflammatory-Bowel-Disease-IBD-and-Immune-Deficiency-and-Hemophilia-and-Multiple-Sclerosis-MS-and-Rare-Disease) + Amber-Specialty-Pharmacy-Patient + Health-System-and-Payor-Customer + Pharma-Limited-Distribution-Drug-Customer (Vertex-Casgevy + Amgen-Tezspire + Sarepta-Elevidys + Roche-Roctavian + bluebird-bio-Lyfgenia + Eli-Lilly-Kisunla + Biogen-Leqembi + Neurocrine-Crenessity + Janssen-Tremfya-and-Stelara + AbbVie-Skyrizi-and-Vyalev) customer base. The company has distinctive multi-cycle Option-Care-Health-and-Bannockburn-IL-and-Home-Infusion-and-Specialty-Pharmacy heritage: founded 1979 as Option-Care-historical-Home-Infusion-Pioneer + 2007-Walgreens-Boots-Alliance-Option-Care-Acquired + 2017-Walgreens-Boots-Alliance-Option-Care-Spin-Off-to-Madison-Dearborn-Private-Equity + 2019-Option-Care-and-BioScrip-Merger-Reverse-Morris-Trust-with-HC-Group-Holdings ($1.2B+); 2019-NASDAQ-Option-Care-Health-IPO; 2019-2024 substantial multi-cycle Home-Infusion-and-Specialty-Pharmacy-Volume-Growth; 2024-Amber-Specialty-Pharmacy-acquired ($465M+ providing emerging-multi-cycle-Amber-Specialty-Pharmacy-Limited-Distribution-Drug-and-Specialty-Pharmacy); multi-cycle-disciplined-Home-Infusion-and-Specialty-Pharmacy-Capital-Management; John-Rademacher-CEO-since-2019-Merger-CEO + Multi-Cycle-Option-Care-Health-Capital-Management leadership-continuity. FY2025 closes with selected various aggregate revenue ~$5.55-6.10B (~6-12% YoY-reflecting Home-Infusion-and-Specialty-Pharmacy-Growth + emerging-multi-cycle-Amber-Specialty-Pharmacy-Acquired-2024-Integration + emerging-Site-of-Care-Shift-from-Hospital-to-Home-Infusion), adjusted EBITDA ~$400-475M (~7-8% margins), adjusted EPS ~$1.30-1.65, net debt ~$1.05-1.30B (~2.4-3.0x leverage), and ~165-170M shares outstanding under President & CEO John Rademacher (since-2019-Merger-CEO). The Home-Infusion-Acute-and-Chronic-and-Rare-Complex-and-Amber-Specialty-Pharmacy franchise deep-dive covers distinctive multi-cycle ~7,500-8,000 employees + ~Bannockburn-IL-HQ + ~160+ Home-Infusion-and-Specialty-Pharmacy-Pharmacy-and-Ambulatory-Infusion-Suite across US-National, Home-Infusion-Acute-and-Chronic-and-Rare-Complex-Disease ~82-88% revenue + Amber-Specialty-Pharmacy ~12-18% revenue, substantial multi-cycle Home-Infusion-Patient + Amber-Specialty-Pharmacy-Patient + Health-System-and-Payor-Customer + Pharma-Limited-Distribution-Drug-Customer customer base, 2017-Walgreens-Option-Care-Spin-Off-to-Madison-Dearborn + 2019-Option-Care-BioScrip-Merger ($1.2B+) + 2019-NASDAQ-Option-Care-Health-IPO + 2024-Amber-Specialty-Pharmacy-acquired ($465M+) transformational-platform, emerging-multi-cycle Home-Infusion-and-Specialty-Pharmacy-Growth + emerging-Site-of-Care-Shift-from-Hospital-to-Home-Infusion + emerging-Specialty-Drug-Demand-and-Biologics-Infusion + emerging-Rare-and-Complex-Disease-Infusion-Therapy + emerging-Amber-Specialty-Pharmacy-Acquired-2024-Integration + emerging-Limited-Distribution-Drug-Demand-Cycle structural-tailwinds, competing in Home-Infusion-and-Specialty-Pharmacy space with CVS Health/Coram-Specialty-Infusion, BriovaRx-Optum-Rx, Optum Specialty Pharmacy-UnitedHealth, Walgreens/AllianceRx-Prime-Therapeutics-acquired-2024, Cigna/Accredo-Express-Scripts, Diplomat Pharmacy-Optum-acquired, AcariaHealth-Centene-acquired, BioPlus-Carecentrix-CVS-acquired, Encompass Health Home-Infusion, Pharmerica-BrightSpring-Health-Services, Soleo Health-Madison-Dearborn. The John-Rademacher + 2019-Merger-CEO + 2017-Walgreens-Option-Care-Spin-Off-and-2019-Option-Care-BioScrip-Merger-and-2024-Amber-Specialty-Pharmacy-Acquired deep-dive covers John-Rademacher-CEO (since-2019-Merger-CEO + Former-BioScrip-CEO) + multi-cycle-Option-Care-Health-Capital-Management leadership-continuity expertise, multi-cycle-disciplined-Home-Infusion-and-Specialty-Pharmacy-Capital-Management discipline, no-dividend (Cash-Flow-Reinvested-in-Home-Infusion-and-Specialty-Pharmacy-Growth-and-Amber-Acquired-Integration) + multi-cycle-emerging-share-buyback (~$100-300M/yr discretionary). Capital position is Sub-IG (Ba2/BB to Ba1/BB+ ~2.4-3.0x leverage). At ~$24-38 per share, equity value ~$4.00-6.40B, EV ~$5.05-7.70B, providing ~16-26x EPS and ~11-17x EV/EBITDA.